Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Transplants in Myelodysplastic Syndromes

    ... in the elderly. Therefore, an increase in the prevalence of de novo but also of secondary forms after prior chemotherapy or ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Promising news for older AML patients

    ... was effective among patients with both primary de novo AML (68%) and secondary AML (related to myelodysplasia or ...

    Article last updated 07/19/2017 - 11:19am.

  3. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

    ... syndromes (MDS) have worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS ...

    Research Article last updated 03/09/2017 - 1:27pm.

  4. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium

    ... While therapy-related (t)-MDS has worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS ...

    Research Article last updated 02/03/2017 - 10:09am.

  5. Focal Adhesion Kinase as a Potential Target in AML and MDS

    ... who transformed from MDS compared with those with de novo AML. Co-culture with mesenchymal stromal cells (MSCs) increased FAK ...

    Research Article last updated 03/22/2017 - 10:20am.

  6. Therapy-related myelodysplastic syndromes, or are they?

    ... monotherapy, biologically and clinically resemble de novo (d)-MDS more than t-MDS, and therefore may not be truly ...

    Research Article last updated 01/26/2017 - 10:08am.

  7. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... 72.3 [15.6] years), 55 (64.0%) had MDS, 21 (24.4%) had de novo AML, and 10 (11.6%) had AML and a history of MDS. Rheumatoid arthritis ...

    Research Article last updated 02/21/2017 - 10:55am.

  8. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT

    ... Author(s):  Cremers EM, van Biezen A, de Wreede LC, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, ... obtain a homogeneous patient cohort by including only de novo MDS patients who received upfront allogeneic SCT after standard high ...

    Research Article last updated 10/06/2016 - 11:40am.

  9. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... 72.3 [15.6] years), 55 (64.0%) had MDS, 21 (24.4%) had de novo AML, and 10 (11.6%) had AML and a history of MDS. Rheumatoid arthritis ...

    Research Article last updated 02/03/2017 - 1:25pm.

  10. Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki

    ... (P = 0.0001, and P < 0.0001, respectively). As with de novo MDS, multivariate Cox regression analyses revealed that cytogenetic ...

    Research Article last updated 11/02/2016 - 9:24am.